Once-Weekly Semaglutide in Adults with Overweight or Obesity REPLY

被引：0
|
作者：
Wilding, John P. H. [1 ]
Calanna, Salvatore [2 ]
Kushner, Robert F. [3 ]
机构：
[1] Univ Liverpool, Liverpool, Merseyside, England
[2] Novo Nordisk, Soborg, Denmark
[3] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2021年 / 385卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Once-weekly semaglutide increases risk of optic neuropathy
    Reactions Weekly, 2025, 2043 (1) : 10 - 10
  • [22] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Pierre Johansen
    Jonas Håkan-Bloch
    Aiden R. Liu
    Peter G. Bech
    Sofie Persson
    Lawrence A. Leiter
    PharmacoEconomics - Open, 2019, 3 : 537 - 550
  • [23] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Johansen, Pierre
    Hakan-Bloch, Jonas
    Liu, Aiden R.
    Bech, Peter G.
    Persson, Sofie
    Leiter, Lawrence A.
    PHARMACOECONOMICS-OPEN, 2019, 3 (04) : 537 - 550
  • [24] Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg
    Kyrillos, Janine V.
    O'Neil, Patrick M.
    Wharton, Sean
    POSTGRADUATE MEDICINE, 2022, 134 : 1 - 4
  • [25] Semaglutide once-weekly: improved efficacy with a new safety warning
    Coon, Scott A.
    Crannage, Erica F.
    Kerwin, Lara C.
    Guyton, Justinne E.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (11) : 1061 - 1072
  • [26] Gastrointestinal adverse events with once-weekly semaglutide: risk predictors and effect on semaglutide response
    Knop, F. K.
    Harring, S.
    Holst, I.
    Kvist, K.
    Lingvay, I.
    Vilsboll, T.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S290 - S291
  • [27] Treatment with once-weekly semaglutide 2.4 mg improves cardiometabolic risk factors in adults with overweight or obesity and type 2 diabetes: STEP 2 post-hoc analysis
    Deanfield, J. E.
    Davies, M.
    Garvey, W. T.
    Jeppesen, O. K.
    Khalid, U.
    Kosiborod, M.
    Kushner, R. F.
    Laursen, P. N.
    Rubino, D. M.
    Verma, S.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 249 - 249
  • [28] Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg
    Kelly, Aaron S.
    Arslanian, Silva
    Hesse, Dan
    Iversen, Aske Thorn
    Koerner, Antje
    Schmidt, Signe
    Sorrig, Rasmus
    Weghuber, Daniel
    Jastreboff, Ania M.
    OBESITY, 2023, 31 (08) : 2139 - 2149
  • [29] Treatment with Once-Weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity and Type 2 Diabetes: STEP 2 Post-hoc Analysis
    Kushner, Robert F.
    Davies, Melanie J.
    Deanfield, John
    Garvey, W. Timothy
    Jeppesen, Ole
    Khalid, Usman
    Kosiborod, Mikhail N.
    Laursen, Peter N.
    Rubino, Domenica
    Verma, Subodh
    DIABETES, 2021, 70
  • [30] Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity
    Wilkinson, Lua
    Holst-Hansen, Thomas
    Laursen, Peter N.
    Rinnov, Anders R.
    Batterham, Rachel L.
    Garvey, W. Timothy
    OBESITY, 2023, 31 (09) : 2249 - 2259
12345